|
|
||||||||
Departments of Obstetrics, Gynecology, and Reproductive Sciences and of Cell Biology and Physiology, University of Pittsburgh School of Medicine and Magee-Womens Research Institute, Pittsburgh, Pennsylvania 15213
| |
ABSTRACT |
|---|
|
|
|---|
A standard approach
to assessing nitric oxide synthase (NOS) activity in tissue homogenates
is 1) removal of small-molecular-weight substances by
size-exclusion chromatography, 2) adding back of substrates/cofactors in precise concentrations with a radioactive isotope of arginine (Arg), and 3) quantification of labeled
citrulline (Cit) after separation of Arg and Cit by cation-exchange
column chromatography. Using this approach and
L-[2,3-3H]Arg, we found that the major
product(s) was not Cit in cortical homogenates prepared from rat,
mouse, and human kidneys. The product(s) mimicked Cit, insofar as it
passed freely through cation-exchange columns and comigrated with Cit
on both one-dimensional and two-dimensional straight-phase thin-layer
chromatography systems. However, it was clearly resolved from
Cit by precolumn derivatization and reverse-phase HPLC. The maximum
velocity and Michaelis-Menten constant were approximately 100 pmol · mg
protein
1 · min
1 and 100 µM,
respectively, in renal cortical homogenates from rats. The enzyme
activity was the same in the presence or absence of cofactors including
Ca2+, calmodulin, tetrahydrobiopterin, and NADPH. It
was only modestly inhibited by L-Arg analogs and was mainly
in the supernatant after a 100,000 g centrifugation. These
enzyme characteristics contrasted markedly with those simultaneously
obtained for NOS activity in placental homogenates. Thus results from
the conventional NOS activity assay should be viewed cautiously.
kidney; renal cortex; human placenta; rats; mice; humans; nitric oxide synthase; arginine; arginine analogs; chromatography
| |
INTRODUCTION |
|---|
|
|
|---|
NITRIC OXIDE SYNTHASE (NOS) catalyzes the formation of nitric oxide (NO) and citrulline (Cit) from arginine (Arg) and oxygen. The cofactors include Ca2+ and the Ca2+-binding protein calmodulin (CaM), flavin mononucleotide and flavin adenine dinucleotide (FAD), and tetrahydrobiopterin (BH4). All forms of the enzyme require reducing equivalents from NADPH, an additional cofactor. Two isoforms of the enzyme, neuronal NOS (NOS-1) and endothelial NOS (NOS-3), require Ca2+ for activity, whereas the inducible NOS (NOS-2) isoform does not require Ca2+ because it is already tightly bound to the enzyme with CaM (reviewed in Ref. 9).
We recently demonstrated that the renal vasodilation and hyperfiltration of pregnancy are mediated by NO via endothelin (ET) and the endothelial ETB receptor in conscious rats (6, 8). Using these physiological observations to guide our investigations further at the cellular and molecular level, one of our objectives was to determine NOS activity in renal cortical homogenates prepared from nonpregnant and pregnant rats. Because over 90% of renal blood flow is distributed to the cortex (15), we focused specifically on this zone of the kidney.
Using a conventional "NOS activity" assay with L-[2,3-3H]Arg as the labeled substrate (2, 5, 7), we found that the major product(s) was not Cit. Initial clues that the major product(s) formed by renal cortical homogenates was not Cit and the enzyme activity was not NOS included complete independence of Ca2+, on the one hand, and of NADPH, on the other. The major product(s) looked like Cit, insofar as it passed freely through columns containing cation-exchange resin and comigrated with Cit on one- and two-dimensional straight-phase thin-layer chromatography systems. However, the compound(s) was clearly resolved from Cit by precolumn derivatization and reverse-phase HPLC.
| |
METHODS |
|---|
|
|
|---|
Tissue collection. Renal cortex was isolated by blunt dissection from Long-Evans female rats (Harlan Sprague Dawley, Indianapolis, IN or Frederick, MD) and NFR/N mice (National Institutes of Health). Renal cortex was also obtained from human male kidneys provided by the National Disease Research Interchange (Philadelphia, PA). The human kidney tissue was snap-frozen in liquid nitrogen within 6 h of accidental death. Villous tissue was dissected from human placentas that were acquired from normal spontaneous vaginal deliveries or cesarean section, as previously described, and served as a positive control for NOS activity (5, 7).
Tissue homogenates. We previously reported in detail the preparation of tissue homogenates for the NOS activity assay (5, 7). Briefly, tissue was homogenized in a solution containing 50 mM sucrose, 25 mM HEPES, 1.0 mM dithiothreitol, and several protease inhibitors (10 µg/ml each of leupeptin, pepstatin A, chymostatin, antipain, and soybean trypsin inhibitor, as well as 100 µg/ml phenylmethylsulfonyl fluoride). The homogenate was then centrifuged at 10,000 g for 15 min at 4°C. The supernatant was next passed through a desalting column (10DG columns, BioRad, Richmond, CA) with a molecular exclusion size of <6 kDa in order to remove all substrates and cofactors except possibly CaM, which has a molecular mass of ~17 kDa. Finally, particulate and cytosolic fractions were prepared by a second centrifugation at 100,000 g for 60-90 min at 4°C (12).
NOS activity assay. Again, this procedure has been previously described (2, 5, 7). In brief, 100 µl of the homogenate was added to 100 µl of incubation buffer. Except when otherwise indicated, the following final concentrations of cofactors were used: L-Arg, 20 µM; CaM, 10 U/ml; FAD, 10 µM; NADPH, 0.5 mM; BH4, 2 µM; and L-[2,3-3H]Arg, 2.5 µCi/ml or L-[guanido-14C]Arg, 2.5 µCi/ml (NEN, Boston, MA). When enzyme activity was tested in the presence of Ca2+, the final concentration of the cation was 10 µM as verified by Ca2+-sensitive electrode. To assess Ca2+-independent NOS activity, Ca2+ was omitted and EGTA was added to the incubation buffer (final reaction concentration 0.5 mM). Incubations were conducted at 25°C in a shaking water bath usually for 40 min. The enzyme reaction was stopped by adding 1.8 ml of ice-cold buffer containing 80 mM HEPES, 8 mM EDTA, pH 5.2, except for the samples prepared for HPLC, which were stopped by 1.8 ml of ice-cold distilled water. (In pilot experiments, we found that the binding of Arg and the passage of Cit through the cation-exchange columns were not affected by these different stop solutions.) Although nonenzymatic conversion was negligible, it was determined routinely in each experiment using homogenate that had been heated to 60°C for 30 min. The radioactive counts were then subtracted from those generated by the 25°C incubations. This step also accounted for the small, but not trivial, amounts of L-[2,3-3H]Arg or L-[guanido-14C]Arg that eluted from the cation-exchange column. The radiolabeled Cit (and other radiolabeled products; see below) produced in the enzyme reaction was separated from radiolabeled Arg by Dowex AG50W-X8 cation-exchange columns (Na+ form).
To assess enzyme activity in the absence of NADPH, BH4, and/or other cofactors, they were deleted from the incubation cocktail. In some experiments, small-molecular-weight substances were removed instead by dialysis using tubing with a cut-off molecular weight of 1,000. In other experiments, any endogenous NADPH that may have passed through the desalting columns or may not have been removed by dialysis was consumed in a reaction using 20 µM nitroblue tetrazolium at 4°C for 1 h. To determine activity in the absence of CaM, the cofactor was deleted from the incubation cocktail, and either 100 µM trifluperazine or R-24571 was added. Finally, to block NOS activity, either NG-monomethyl-L-arginine (L-NMMA) or NG-nitro-L-arginine methyl ester (L-NAME) was used in the reaction. D-NAME was employed as a negative control. For the data portrayed in Table 1, Lineweaver-Burk analysis was conducted to assess the maximum velocity (Vmax) and Michaelis-Menten constant (Km) of the enzyme in the renal cortex as previously described (5, 7). Initially, a time course (5, 10, 20, and 40 min; duplicate determinations each) was established. Once it was clear that the time course was linear, a single, 30-min time point was used in subsequent assays. Either duplicate or single determinations were performed at the 30-min time point using unlabeled Arg at a final concentration ranging from 10 to 100 µM.
|
Thin-layer chromatography. Both one-dimensional (1-D) and two-dimensional (2-D) straight-phase thin-layer chromatography systems were used as previously reported (7). In both cases, SG-60 plates were utilized (Analtech, Newark, DE). For the 1-D system, a basic mobile phase of chloroform-methanol-ammonium hydroxide-water (5:45:20:10 vol/vol/vol/vol) was employed with clear separation of Arg, ornithine, and Cit Rf values of 0.48, 0.60, and 0.75, respectively). For the 2-D system, the basic mobile phase was used for both directions with excellent separation of Cit from Arg and ornithine, which were themselves poorly separated. Alternatively, excellent separation for Cit was also obtained using an acidic mobile phase (chloroform-methanol-acetic acid-water, 5:45:20:10 vol/vol/vol/vol) in the second direction while achieving some separation of Arg and ornithine.
Reverse-phase HPLC. The samples eluted from the cation-exchange columns were dried and reconstituted in 60 µl of 100 µM L-Cit. Samples were then mixed with an equal volume of o-phthaldialdehyde reagent solution (OPA; Sigma, St. Louis, MO) for a final volume of 120 µl. Cit was separated from the other radiolabeled products in the sample using reverse-phase HPLC similar to that described by Carlberg (4). Briefly, 100 µl of each sample was injected onto a C18 Partisil 10 ODS-3 analytic column (4.6 × 250 mm) that had been equilibrated before injection for 1 h with mobile phase consisting of 11.5% methanol, 5% acetonitrile, and 1% tetrahydrofuran in 10 mM KH2PO4 buffer, pH 5.9. The flow rate for the pump was 1.5 ml/min, and the absorbance of the sample was monitored at a wavelength of 340 nm. After injection, the eluate was collected in 30-s fractions for 20 min. Each fraction was mixed with scintillation cocktail and counted for 10 min.
| |
RESULTS |
|---|
|
|
|---|
Table 1 depicts the Vmax and Km for enzyme activity in renal cortical homogenates from rats. (Because the relationship correlation between 1/V and 1/[substrate] was >0.99 for each homogenate, we presume the rather large SEs are due to biological variation among rats.) These enzyme characteristics were not significantly affected by deleting Ca2+ and adding 0.5 mM EGTA (or even a higher EGTA concentration of 5.5 mM). The lack of Ca2+ dependency by enzyme activity was also observed using renal cortical homogenates from cesarean section-derived, barrier-raised Long-Evans female rats (n = 2) and from a pool of 10 NFR/N female mice (data not shown).
To verify that the NOS enzyme assay was reliable, we used human term
villous placental homogenates as a positive control for the endothelial
form of NOS (5, 7). Table 2
shows that, as expected, by deleting Ca2+ and adding 0.5 mM
EGTA, virtually all of the activity was inhibited. Yet, when tested
side-by-side in the same assay under identical conditions, enzyme
activity in renal cortical homogenates from rats was again virtually
unaffected by deleting Ca2+ and adding EGTA (Table 2).
|
Additional enzyme characteristics for human term villous placenta and
rat renal cortex are also presented in Table 2. By deleting NADPH and
BH4, the NOS activity in the placenta was abolished. In
contrast, enzyme activity in rat renal cortex was not diminished. To be
certain that all of the endogenous NADPH was removed, the kidney
homogenates were subjected to two passages through the desalting
columns or extensive dialysis and then reaction with nitroblue
tetrazolium to consume any residual NADPH. The robust enzyme activity
was the same irrespective of nitroblue tetrazolium treatment. In
contrast, NOS activity of the human placental homogenates tested in the
presence of NADPH was greatly diminished when subjected to the same
nitroblue tetrazolium treatment (data not shown). To determine the CaM
dependency of enzyme activity, trifluperazine or R-24571 was
used. Although these CaM antagonists clearly reduced activity in the
term human villous placenta (7), they did not affect the
activity in the renal cortex conducted in the presence of 10 µM Ca2+ (n = 3 rats): control, 3.1 ± 0.1; trifluperazine, 3.2 ± 0.1; and R-24571, 3.3 ± 0.1 nmol · mg protein
1 · 40 min
1.
In the presence of Ca2+, the cytosolic and particulate
activities in renal cortical homogenates from three rats were 498 ± 73 and 54 ± 20 pmol · mg
protein
1 · 40 min
1, respectively.
When factored for tissue wet weight, 96.5 ± 1.0% of the activity
resided in the cytosolic fraction. In the absence of Ca2+,
the cytosolic and particulate activities were 519 ± 66 and
81 ± 20 pmol · mg protein
1 · 40 min
1, respectively. When factored for tissue wet
weight, 94.0 ± 2.1% of the activity resided in the cytosolic fraction.
Although NOS activity in the human term villous placenta was inhibited
90.3 ± 3.6% by L-NAME (n = 3 placentas), enzyme activity was only modestly reduced in the
rat renal cortex by this Arg analog (Table
3). In experiments
using an additional three rats, enzyme activity was inhibited
by 13-47% using L-NAME-to-Arg concentration ratios of
20-50 to 1. The degree of inhibition did not vary consistently with the presence or absence of Ca2+. Table
4 depicts the data for human
male kidney cortex. The enzyme activity was again mostly
independent of NADPH and BH4 and was little affected by
L-NAME. Furthermore, the enzyme activity was lower than in
the rat kidney cortex, which may reflect the longer interval before
freezing (see METHODS) or inherently lower activity in
human kidneys.
|
|
To test whether the product(s) was Cit, we performed both 1-D and 2-D straight-phase thin-layer chromatography. The enzyme assay was conducted in the presence of all cofactors, and the reaction was first passed through a cation-exchange column before thin-layer chromatography. Using 1-D thin-layer chromatography, 95.5 and 96.3% of total counts, respectively, comigrated with unlabeled Cit for the human placenta and rat renal cortex. In the 2-D system using the basic mobile phase in both directions, 93.1% of applied counts comigrated with Cit for the human placenta. When the assay was carried out both with and without Ca2+ for the rat renal cortex, 81.4 and 86.0% of the total counts comigrated with Cit, respectively. In the 2-D system using the basic mobile phase in the first direction and the acidic phase in the second direction, 89.1 and 81.4% of the counts comigrated with Cit.
Further testing was conducted using precolumn derivatization and
reverse-phase HPLC (Fig. 1). In Fig.
1A, most of the radioactive product generated from the
placental homogenates eluted with unlabeled Cit with a peak at
fraction 15. A minor peak detected at fraction 7 was independent of heat inactivation. By contrast, for the renal cortical homogenates from rats, most of the radioactivity eluted much
earlier, with a peak at fractions 6-8, regardless of
the presence (Fig. 1B) or absence (Fig. 1C) of
Ca2+, NADPH, and BH4. In the presence of
Ca2+ and other cofactors, an additional small amount of
radioactivity eluted with unlabeled Cit. Interestingly, this peak
persisted, albeit to a smaller degree, in the absence of
Ca2+ and cofactors. Comparable results were obtained using
another reverse-phase HPLC system and derivatization with phenyl
isothiocyanate as described by Buzzigoli and co-workers (Ref.
3; data not shown).
|
The radioactive product(s) generated by renal cortical homogenates was
virtually unretained by the reverse-phase HPLC column irrespective of
derivatization with OPA (Fig.
2A). (Similar results were
observed when phenyl isothiocyanate was used as a derivatization reagent; data not shown.) As expected, the mobility of
[3H]Cit generated by NOS activity in placental
homogenates was shifted by derivatization (Fig. 2B). We
observed that background counts associated with the heat-inactivated
tissue homogenates inexorably increased over several months. As noted
in METHODS, the counts associated with the heat-inactivated
homogenate were subtracted from the enzyme activity measured at 25°C
in each assay, so they were accounted for. Nevertheless, we were
successful in reducing this background by incubating an aliquot of the
stock L-[2,3-3H]Arg with a small amount of
anion-exchange resin for 10 min at 25°C immediately before addition
to the incubation cocktail. This spontaneously generated breakdown
product(s) was also virtually unretained by the reverse-phase HPLC
column and eluted with a peak at fraction 7 (Fig.
2C).
|
To begin investigating the identity of the compound(s) in question, we
tested several Arg metabolites by comparing their Rf values
vs. Cit on 1-D straight-phase thin-layer chromatographs. Because the
unidentified product(s) comigrates with Cit in this chromatographic
system (see above), we reasoned that candidate molecules not
comigrating with Cit could be excluded. Using this approach, we were
able to rule out Arg (radiolabeled precursor); hydroxyarginine (NOS
intermediate or P-450 product); ornithine (arginase);
argininosuccinate (urea cycle); polyamines including spermine,
spermidine, and putrescine (ornithine decarboxylase); proline
(via ornithine transaminase and glutamic acid); and
phosphoarginine (data not shown). Using 10 mM
L-valine, we found a reduction in the activity of renal
cortical homogenates from 170 to 32 pmol · mg
protein
1 · 40 min
1, while
activity in placental villous homogenate was mostly unaffected, 124 to
116 pmol · mg protein
1 · 40 min
1 (Cit).
| |
DISCUSSION |
|---|
|
|
|---|
A standard approach to assessing NOS activity in tissue homogenates is the use of a radioactive isotope of Arg in the assay and then quantification of labeled Cit after separation of Arg and Cit by cation-exchange column chromatography (2, 5, 7). By using this approach, we previously identified NOS activity in the human term villous placenta that was virtually all Ca2+ and calmodulin dependent, inhibited by L-NAME, and primarily located in the particulate fraction (5, 7). If fact, we used placental homogenate as a positive control for the current investigation of enzyme activity in the renal cortex.
Our goal was to quantify NOS activity in renal cortical homogenates from nonpregnant and midterm pregnant rats, because our physiological studies demonstrated that gestational renal vasodilation and hyperfiltration were mediated by NO (8). Unfortunately, our goal was not achieved because we found that the standard NOS activity assay when applied to renal cortical homogenates did not reflect NOS activity or yield Cit as the major product.
When we measured Vmax and Km of the putative NOS activity in renal cortical homogenates of nonpregnant female rats, we found that Vmax was the same regardless of the presence or absence of Ca2+. By contrast, deletion of Ca2+ from the enzyme reaction for term placental villous homogenates virtually eliminated all activity as previously reported (5, 7). In a similar vein, whereas CaM antagonists greatly reduced NOS activity in the term human villous placenta (7), no such reduction was observed for the putative NOS activity in rat renal cortex.
We next considered the possibility of a Ca2+-independent isoform of NOS, perhaps one of the inducible NOS isoforms that had been identified in the kidney at least at the level of mRNA by RT-PCR (11). To eliminate the possibility of low-grade, chronic renal interstitial nephritis contributing to the induction of NOS, we tested the enzyme activity in cesarean section-derived, barrier-raised female rats. However, comparable activity was again observed regardless of the presence or absence of Ca2+. The enzyme activity observed in renal cortical homogenates prepared from female mice and male humans was also Ca2+ independent. Finally, the Km was higher than most values published for the various NOS isoforms (9).
Another attribute of NOS isoforms is that they are inhibited by various analogs of L-Arg (9). In agreement with our previous work (5, 7), the NOS activity in homogenates from term human villous placenta was reduced, on average, by 90% using L-NAME. By contrast, the inhibition of the putative NOS activity in tissue homogenates prepared from rat or human renal cortex was at best partial, ranging from 8 to 47%.
An absolute requirement for NOS activity is the contribution of reducing equivalents from NADPH (9, 11). When NADPH (and BH4) was deleted from the enzyme reaction for term human villous placenta, virtually all of the NOS activity was abolished. However, omission of these cofactors hardly affected the enzyme activity of either rat or human renal cortex.
Both the Ca2+- and NADPH-independent characteristics of the putative NOS activity in the renal cortex prompted us to further investigate whether the major product formed was indeed Cit. When the radioactive product(s) eluting from the cation-exchange column was applied to either 1-D or 2-D straight phase thin-layer chromatography, the product consistently comigrated with unlabeled Cit, which was well-separated from both Arg and ornithine in these chromatographic systems. However, because the cofactor requirements did not fit with NOS, we further performed reverse-phase HPLC. Using two different precolumn derivatization procedures and reverse-phase HPLC systems, the major radioactive product(s) formed by the rat kidney cortex and eluted from the cation-exchange columns was clearly not Cit.
Although we tried to identify the product(s) in question using gas chromatography-mass spectrometry, we were unsuccessful. Thus we do not currently know its identity, although the L-[2,3-3H]Arg may spontaneously decay into the compound(s), which is partly adsorbed by anion-exchange resin. Because the retention (or lack thereof) of the product was mostly unaffected on reverse-phase HPLC by derivatization either with phenyl isothiocyanate or o-phthaldialdehyde, it is probably not a primary or secondary amine. Moreover, the product did not comigrate with many of the common Arg metabolites on 1-D straight-phase thin-layer chromatography. In collaboration with Drs. J. Roberts and S. Sladek of the Magee-Womens Research Institute, Univ. of Pittsburgh, and R. Hoffman of the Dept. of Surgery, Univ. of Pittsburgh, the product was also identified in rat uterus and mouse jejunum, respectively, using L-[14C]Arg substrate labeled at all of the carbon atoms (personal communications, unpublished data).
Using L-[guanido-14C]Arg and rat
renal cortical homogenates, we again found comparable activity in the
presence and absence of NADPH/BH4, i.e., 784 vs. 826 pmol · mg protein
1 · 60 min
1, respectively. Inexplicably, these values
were twice those observed using the same homogenate run concurrently
with L-[2,3-3H]Arg, i.e., 484 vs. 366 pmol · mg protein
1 · 60 min
1. In the former, however, we were uncertain of the
ability of the cation-exchange columns to completely retain any urea
that might be formed.
To recapitulate, the enzyme activity that we have identified in the renal cortex is unlikely to be NOS for three main reasons: 1) the activity is independent of NADPH, 2) it is poorly inhibited by Arg analogs, and 3) the major product is not Cit. Interestingly, both R. Hoffman (unpublished observation) and we (see RESULTS) observed reduction of product(s) formation by L-valine, suggesting involvement of the arginase pathway. It is conceivable, however, that L-valine may not be a specific arginase inhibitor. Moreover, arginase is supposed to be heat stable (10), and in our hands, activity was completely lost with incubation at 55-60°C for 30 min. The kidney is rich in L-amino acid oxidase (1) and diamine oxidase (13), which may contribute to the formation of the unidentified Arg metabolite(s) observed herein. Finally, we cannot conclusively rule out that the unidentified compound(s) arises from a labeled contaminant within the Arg preparation rather than from the Arg itself, although this possibility seems unlikely for several reasons. First, cold Arg readily competes for the formation of radiolabeled product. Thus we were able to derive Michaelis-Menten kinetics (see RESULTS). The cold Arg was >99% pure by thin-layer chromatography as reported by the manufacturer (Sigma). Second, we consistently observed the unidentified compound(s) using many different lots of L-[2,3-3H]Arg as well as with [14C]Arg. Third, we often ran our labeled Arg on 1-D straight-phase thin-layer chromatographs and verified the high purity claimed by the manufacturer.
A recent report by Singh et al. (14) suggested the presence of a new NOS isoform in the whole rat kidney that was Ca2+, CaM, and NADPH independent, as well as relatively resistant to inhibition by L-NAME and S-ethyl-isothiourea and mainly present in the cytosolic fraction. These enzyme characteristics mirror our own. However, the work of Singh et al. (14) and our own do not entirely agree, insofar as they (14) demonstrated the major product to be Cit by ion pair reverse-phase HPLC, whereas we showed that it was not Cit, also by reverse-phase HPLC, but using precolumn derivatization procedures. We considered two potential explanations for this discrepancy. The first and most likely was that our procedures of precolumn derivatization and reverse-phase HPLC permitted resolution of Cit from the unknown product(s), while the HPLC method of Singh and colleagues (14) did not. In support of this possibility, we observed that both unlabeled Cit standard and labeled Cit generated by placental homogenates, when they were not derivatized, eluted in the same fractions as the unknown compound(s) produced by renal cortical homogenates. Second, we also observed generation of Cit by renal cortical homogenates that was inhibited by heat, but it was a minor product. Interestingly, this Cit formation was not completely inhibited by deleting NADPH/BH4, similar to the work of Singh et al. (14). However, perhaps significant counts associated with the unknown compound(s) were eluted in the void volume and discounted by Singh and colleagues (an HPLC profile of radioactive products was not presented). Nevertheless, it is difficult to understand how the enzyme responsible for the residual Cit formation could have been a NOS isoform as Singh and co-workers (14) proposed, since the activity was independent of NADPH.
Perspectives
The conventional "NOS activity" assay when applied to renal cortical homogenates does not reflect NOS activity or produce Cit as a major product. The extent to which homogenates prepared from other tissues might yield similar misleading results is presently unknown. However, the product(s) that behaved like Cit in several chromatographic systems (except for reverse-phase HPLC with precolumn derivatization) was observed in mouse jejunum and rat uterus. Ultimately, the usefulness of the conventional "NOS activity" assay as a bona fide measure of NOS activity may be inversely related to the level of expression of the enzyme activity producing the unknown product(s) that masquerades as Cit. We considered that one possible way to assess NOS activity in renal cortical homogenates using the conventional Arg-to-Cit conversion assay and cation-exchange chromatography might be to subtract the enzyme activities measured in the presence and absence of NADPH/BH4 or Arg analogs such as L-NAME (assuming the latter are specific for NOS). Unfortunately, the enzyme activities measured in the presence and absence of these cofactors or Arg analogs were both robust, thereby making this approach difficult, i.e., NOS activity was relatively low and contributed little to the total activity as assessed by this methodology. Thus future investigation of NOS activity by Arg-to-Cit conversion in renal cortical homogenates as well as perhaps in homogenates of other tissues will require chromatography techniques that are powerful enough to uniquely resolve Cit (e.g., cation-exchange chromatography followed by precolumn derivatization and reverse-phase HPLC as in the present work). Possibly, C18 Sep-Pak methodology can be substituted for the reverse-phase HPLC step, thereby simplifying the procedure.| |
ACKNOWLEDGEMENTS |
|---|
We thank A. Pastuszyn of the Univ. of New Mexico School of Medicine for performing the initial reverse-phase HPLC studies and S. Kauffman for expert clerical assistance.
| |
FOOTNOTES |
|---|
This work was supported by National Institutes of Health Grants KO4-HD-01098 and RO1-HD-30325.
Present address of A. K. Davis: Dept. of Pharmaceutical Sciences, Wayne State University, Detroit, MI 48202.
Address for reprint requests and other correspondence: K. P. Conrad, Magee-Womens Research Institute, 204 Craft Ave., Pittsburgh, PA 15213 (E-mail: rsikpc{at}mail.magee.edu).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpregu.00309.2001
Received 31 May 2001; accepted in final form 21 September 2001.
| |
REFERENCES |
|---|
|
|
|---|
1.
Blanchard, M,
Green DE,
Nocito V,
and
Ratner S.
L-Amino acid oxidase of animal tissue.
J Biol Chem
155:
421-440,
1944
2.
Bredt, DS,
and
Snyder SH.
Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme.
Proc Natl Acad Sci USA
87:
682-685,
1990
3.
Buzzigoli, G,
Lanzone L,
Ciociaro D,
Frascerra S,
Cerri M,
Scandroglio A,
Coldani R,
and
Ferrannini E.
Characterization of a reversed-phase high-performance liquid chromatographic system for the determination of blood amino acids.
J Chromatography
507:
85-93,
1990[Medline].
4.
Carlberg, M.
Assay of neuronal nitric oxide synthase by HPLC determination of citrulline.
J Neurosci Meth
52:
165-167,
1994[Web of Science][Medline].
5.
Conrad, KP,
and
Davis AK.
Nitric oxide synthase activity in placentae from women with preeclampsia.
Placenta
16:
691-699,
1995[Web of Science][Medline].
6.
Conrad, KP,
Gandley RE,
Ogawa T,
Nakanishi S,
and
Danielson LA.
Endothelin mediates renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats.
Am J Physiol Renal Physiol
276:
F767-F776,
1999
7.
Conrad, KP,
Vill M,
McGuire PG,
Dail WG,
and
Davis AK.
Expression of nitric oxide synthase by syncytiotrophoblast in human placental villi.
FASEB J
7:
1269-1276,
1993[Abstract].
8.
Danielson, LA,
and
Conrad KP.
Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats.
J Clin Invest
96:
482-490,
1995.
9.
Griffith, OW,
and
Stuehr DJ.
Nitric oxide synthases: properties and catalytic mechanism.
Ann Rev Physiol
57:
707-736,
1995[Web of Science][Medline].
10.
Kaysen, GA,
and
Strecker HJ.
Purification and properties of arginase of rat kidney.
Biochem J
133:
779-788,
1973[Web of Science][Medline].
11.
Kone, BC,
and
Baylis C.
Biosynthesis and homeostatic roles of nitric oxide in the normal kidney.
Am J Physiol Renal Physiol
272:
F561-F578,
1997
12.
Reid, E,
and
Williamson R.
Centrifugation.
In: Methods in Enzymology. New York: Academic, 1974, vol. XXXI, p. 713-733.
13.
Schwelberger, HG,
and
Bodner E.
Purification and characterization of diamine oxidase from porcine kidney and intestine.
Biochim Biophys Acta
1340:
152-164,
1997[Medline].
14.
Singh, R,
Pervin S,
Rogers NE,
Ignarro LJ,
and
Chaudhuri G.
Evidence for the presence of an unusual nitric oxide- and citrulline-producing enzyme in rat kidney.
Biochem Biophys Res Com
232:
672-677,
1997[Web of Science][Medline].
15.
Valtin, H,
and
Schafer JA.
Renal Function (3rd ed.). Boston, MA: Little, Brown, 1995, p. 97.
This article has been cited by other articles:
![]() |
S. Janssens, P. Pokreisz, L. Schoonjans, M. Pellens, P. Vermeersch, M. Tjwa, P. Jans, M. Scherrer-Crosbie, M. H. Picard, Z. Szelid, et al. Cardiomyocyte-Specific Overexpression of Nitric Oxide Synthase 3 Improves Left Ventricular Performance and Reduces Compensatory Hypertrophy After Myocardial Infarction Circ. Res., May 14, 2004; 94(9): 1256 - 1262. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |